PRESENTATION

Q3 2024 — Presentation

Q3 2024PDF · 13 pages195 KB
Elevance Health
3Q 2024 Earnings Presentation
October 17, 2024

-- 1 of 13 --

2
Key Highlights
• 	Elevance Health third quarter results were below expectations primarily due to the unprecedented mix
shift in Medicaid membership related to eligibility redeterminations
• 	3Q 2024 operating revenue of $44.7B grew 5.3% year-over-year
• 	3Q 2024 adjusted diluted EPS of $8.37
• 	3Q 2024 adjusted operating gain of $2.4B
3Q 2024 Results
1
• 	2024 adjusted diluted EPS guidance of approximately $33 accounts for the timing mismatch between
Medicaid rates and the higher acuity of our members, partially offset by targeted medical management
and proactive actions to enhance operating efficiencies
• 	We now expect the 2024 benefit expense ratio to be approximately 88.5% and operating cash flow to be
approximately $4.5 billion, principally due to headwinds in the Medicaid business
• 	We expect strong acceleration in revenue growth in 2025, in line with our long-term growth algorithm, in the
high single-digit percentage range and, at this point in time, growth in 2025 adjusted diluted EPS in at least
the mid single-digit percentage range
• 	Commercial businesses performing well and on track to achieve financial objectives; individual exchange
business delivering particularly strong growth, as we prepare to expand our footprint in 2025
• 	Scaling our enterprise flywheel for growth as we accelerate capabilities and services in Carelon through
an expanding customer base and the buildout of a home-based care management business
2024 & 2025 Outlook
2
• 	Earnings power of our diverse and complementary businesses remains strong, and we are making the right
investments to position Elevance Health for long-term, sustainable growth
• 	Issues impacting the Medicaid managed care industry are timebound, and we are partnering with states to
ensure rising acuity is reflected in rates
• 	Pleased with positioning for 2025 Medicare Advantage bids, which promote access to high-quality,
comprehensive care for our members; we expect to grow in line or slightly better than the market
• 	Expanding Carelon capabilities in support of long-term growth and value creation
Strategic Focus Areas
3

-- 2 of 13 --

33
Key Highlights
• 	Elevance Health third quarter results
reflect a challenging and dynamic
operating environment primarily due
to the timing mismatch between
Medicaid rates and acuity
• 	Operating revenue of $44.7B on
improved premium yields in Health
Benefits, partially offset by the impact
of membership attrition in Medicaid
• 	Benefit expense ratio of 89.5%
increased 270 basis points driven
primarily by pressure in Medicaid
• 	Adjusted operating expense ratio of
9.6% highlights disciplined and
proactive expense management
3Q 2024 Results
Change	3Q 2023	3Q 2024	Elevance Health
5.3%	$42.5B	$44.7B	Operating Revenue 1
270 bps	86.8%	89.5%	Medical Loss Ratio
(150) bps	11.1%	9.6%	Adjusted Operating Expense Ratio1,2
(5.6%)	$2.5B	$2.4B	Adjusted Operating Gain1,2
(70) bps	6.0%	5.3%	Adjusted Operating Margin 1,2
11.8%	$493M	$551M	Net Investment Income
(6.9%)	$8.99	$8.37	Adjusted diluted EPS2
$0.1B	$2.6B	$2.7B	Operating Cash Flow
1. 	See “Basis of Presentation” on slide 10 herein.
2. 	See “GAAP Reconciliation” on slides 11 and 12 herein.
Enterprise Results

-- 3 of 13 --

44
Key Highlights
• 	Health Benefits revenue growth re-
accelerating
• 	Operating revenue grew 4.2% driven
primarily by higher premium yields,
partially offset by declines in
Medicaid membership
• 	Operating gain was impacted by
unfavorable mix shift in Medicaid
membership related to eligibility
redeterminations
• 	Membership of 45.8M reflects attrition
in Medicaid, partially offset by strong
growth in Employer Group fee-based
and ACA health plan membership
Change	3Q 2023	3Q 2024	Health Benefits
4.2%	$36.7B	$38.3B	Operating Revenue 1
(12.5%)	$1.8B	$1.6B	Operating Gain1
(80) bps	5.0%	4.2%	Operating Margin 1
(3.3%)	47.3M	45.8M	Membership 2
1. 	See “Basis of Presentation” on slide 10 herein.
2. 	Health Benefits Membership for the three months ended September 30, 2023, is restated to reflect a change in BlueCard® membership to align to the Blue Cross Blue Shield
Association reporting methodology. For the three months ended September 30, 2023, BlueCard® membership has been restated lower by 19K.
Health Benefits
3Q 2024 Results

-- 4 of 13 --

55
Key Highlights
• 	Carelon is delivering innovative
solutions aligned with our strategy of
controlling the levers than matter
• 	Serves as the enterprise flywheel for
growth, integrating physical,
behavioral, social and pharmacy
services to deliver whole health,
affordably
• 	CarelonRx operating revenue of $9.1
billion includes the acquisition of
Paragon Healthcare and strong
external member growth; operating
gain of $619 million reflects growth in
product revenue
• 	Carelon Services operating revenue of
$4.6 billion grew 32% driven by the
launch and growth of risk-based
products and is on track to exceed the
upper end of our initial outlook of low
twenties percentage revenue growth;
operating gain of $184 million
3Q 2024 Results
Change	3Q 2023	3Q 2024	Carelon
14.6%	$12.0B	$13.8B	Operating Revenue 1
20.0%	$669M	$803M	Operating Gain1
20 bps	5.6%	5.8%	Operating Margin 1
3.8%	77.3M	80.2M	Adjusted Scripts
(3.3%)	104.8M	101.3M	Consumers Served
1. 	See “Basis of Presentation” on slide 10 herein.
Health Services

-- 5 of 13 --

66
Flywheel Supports Our Long-Term Growth Algorithm
Health Benefits
Optimize
the Core
Invest in
Growth
Accelerate
Targeting at least 12% average annual growth in
Adjusted Diluted Earnings Per Share
Approximately 46M medical members
balanced across commercial,
Medicaid and Medicare, leveraging
the assets and capabilities of Carelon
to accelerate growth
Integrated portfolio of whole health
solutions connecting care across
physical, behavioral, social, and
pharmacy needs to bend the cost
curve, enhance consumer experiences,
and deliver whole health, affordably
Health Services

-- 6 of 13 --

77
Adjusted Operating Gain – Upper Single Digit to Low Double Digit CAGR 1
Long-Term Growth Algorithm
Revenue Growth
Upper Single Digit CAGR 1
Adjusted Operating Margin
Expanding to 6.5% - 7.0% by 2027
Capital Deployment
Approximately 4% Contribution to
Adjusted Diluted EPS CAGR 1
Health Benefits
Mid to Upper Single Digit CAGR
Driven by membership growth, cost trend, geographic
expansion, and growth in specialized populations
Carelon Services
Upper Teens to Low Twenties CAGR
Driven by risk-based revenue growth including M&A
CarelonRx
Low-Double Digit CAGR
Driven by script volumes and drug mix
Transforming our business
processes by leveraging new
technologies across operations
Commitment to operating
efficiency and optimizing core
businesses
Effective medical management
Underwriting discipline
Share Repurchases
Organic Reinvestment
Programmatic M&A targeting
integrated solutions that
strengthen health plan
competitiveness
+ 	+
Targeting at least 12% average annual growth in Adjusted Diluted EPS
1. 	CAGR = Compound Annual Growth Rate Target.

-- 7 of 13 --

88
Committed to Strong Growth Over the Long-Term
M&A/ Organic
Reinvestment
50%
Share
Repurchase
30%
Dividends
20%
5.3%
6.5% – 7.0%
2022 	2027
Target
$156B
Upper Single
Digit CAGR2,3
2022 	2027
Target
Elevance Health
5.8%
Mid to Upper
Single Digit
2022 	2027
Target
$41B
Mid Teens
CAGR2,3
2022 	2027
Target
Carelon 4
4.3%
5.5% – 6.5%
2022 	2027
Target
$138B
Mid to Upper
Single Digit
CAGR2,3
2022 	2027
Target
Health Benefits
Capital
Allocation
Targeting at least 12% average annual
growth in Adjusted Diluted EPS
Operating
Margin 1
Revenue1
(in Billions)
1. 	2022 Operating Revenue and Operating Margin for Health Benefits, Carelon, and Elevance Health have been updated to reflect restated financials.
2. 	CAGR = Compound Annual Growth Rate Target.
3. 	Five-Year CAGR target for 2022 – 2027.
4. 	The CAGR target for revenue from 2022 – 2027 and the operating margin target in 2027 for Carelon includes: (i) a low double-digit revenue CAGR and 6.0% – 6.5% operating margin
target for CarelonRx, and (ii) an upper teens to low twenties revenue CAGR and mid to upper single-digit operating margin for Carelon Services.

-- 8 of 13 --

9
Forward-Looking Statements
This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our
views about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,”
“estimate,” “project,” “forecast,” “plan” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial
projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services;
and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our
control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place
undue reliance on these forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other
disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect
our business. Except to the extent required by law, we do not update or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof.
These risks and uncertainties include, but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and implement sufficient
premium rates; the impact of large scale medical emergencies, such as public health epidemics and pandemics, and other catastrophes; the impact of new or changes in
existing federal, state and international laws or regulations, including laws and regulations impacting healthcare, insurance, pharmacy services and other diversified products
and services, or their enforcement or application; the impact of cyber-attacks or other privacy or data security incidents or our failure to comply with any privacy, data or security
laws or regulations, including any investigations, claims or litigation related thereto; failure to effectively maintain and modernize our information systems, or failure of our
information systems or technology, including artificial intelligence, to operate as intended; failure to effectively maintain the availability and integrity of our data; changes in
economic and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to
changes in the industry and develop and implement strategic growth opportunities; risks and uncertainties regarding Medicare and Medicaid programs, including those related
to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star ratings
and other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other
liabilities associated with litigation, government investigations, audits or reviews; our ability to contract with providers on cost-effective and competitive terms; risks associated
with providing healthcare, pharmacy and other diversified products and services, including medical malpractice or professional liability claims and non-compliance by any party
with the pharmacy services agreement between us and CaremarkPCS Health, L.L.C.; risks associated with mergers, acquisitions, joint ventures and strategic alliances; possible
impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in the payment of
dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our common
stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness and
the risk that increased interest rates or market volatility could impact our access to or further increase the cost of financing; a downgrade in our financial strength ratings; the
effects of any negative publicity related to the health benefits industry in general or us in particular; events that may negatively affect our licenses with the Blue Cross and Blue
Shield Association; intense competition to attract and retain employees; risks associated with our international operations; and various laws and provisions in our governing
documents that may prevent or discourage takeovers and business combinations.

-- 9 of 13 --

10
Non-GAAP Measures and Basis of Presentation
This document references non-GAAP measures. These non-GAAP measures are intended to aid investors when comparing Elevance Health’s financial results among periods and
are not intended to be alternatives to any measure calculated in accordance with GAAP. Reconciliations of these non-GAAP measures to the most directly comparable measures
calculated in accordance with GAAP are available on the last slide of this document.
Operating revenue and operating gain/loss are the key measures used by management to evaluate performance in each of its reporting segments, allocate resources, set
incentive compensation targets and to forecast future operating performance. Operating gain/loss is calculated as total operating revenue less benefit expense, cost of
products sold and operating expense. It does not include net investment income, net gains/losses on financial instruments, interest expense, amortization of other intangible
assets and gains/losses on extinguishment of debt or income taxes, as these items are managed in a corporate shared service environment and are not the responsibility of
operating segment management. Operating Margin is defined as operating gain divided by operating revenue. Each of these measures is provided to further aid investors in
understanding and analyzing Elevance Health’s operating and financial results.

-- 10 of 13 --

11	11
Elevance Health GAAP Reconciliation — Shareholders’ Net Income
and Shareholders’ Earnings Per Diluted Share Nine Months Ended Sep 30	Three Months Ended Sep 30
Change	2023	2024	Change	2023	2024	(In millions, except per share data)
8.4%	$5,131	$5,562	(21.2%)	$1,289	$1,016	Shareholders' net income
Add / (Subtract):
5	680	2	669	Litigation and settlement expenses1
697	268	697	268	Business optimization charges 1
358	371	124	125	Net losses on financial instruments
668	400	212	122	Amortization of other intangible assets
154	158	73	42	Transaction and integration related costs1
—	(201)	—	39	Loss (gain) on sale of business
(470)	(432)	(270)	(329)	Tax impact of non-GAAP adjustments
1,412	1,244	838	936	Net adjustment items
4.0%	$6,543	$6,806	(8.2%)	$2,127	$1,952	Adjusted shareholders' net income
10.4%	$21.56	$23.81	(20.0%)	$5.45	$4.36	Shareholders’ earnings per diluted share
Add / (Subtract):
0.02	2.91	0.01	2.87	Litigation and settlement expenses1
2.93	1.15	2.95	1.15	Business optimization charges 1
1.50	1.59	0.52	0.54	Net losses on financial instruments
2.81	1.71	0.90	0.52	Amortization of other intangible assets
0.65	0.68	0.31	0.18	Transaction and integration related costs1
—	(0.86)	—	0.17	Loss (gain) on sale of business
(1.97)	(1.85)	(1.14)	(1.41)	Tax impact of non-GAAP adjustments
5.93	5.33	3.54	4.01	Net adjustment items
6.0%	$27.49	$29.14	(6.9%)	$8.99	$8.37	Adjusted shareholders’ earnings per diluted share
Nine Months Ended Sep 30	Three Months Ended Sep 30
Change	2023	2024	Change	2023	2024	(In millions)
8.7%	$6,714	$7,298	(17.0%)	$1,654	$1,373	Income before income tax expense
(1,296)	(1,524)	(493)	(551)	Net investment income
—	(201)	—	39	Loss (gain) on sale of business
358	371	124	125	Net losses on financial instruments
771	845	259	300	Interest expense
668	400	212	122	Amortization of other intangible assets
(0.4%)	$7,215	$7,189	(19.8%)	$1,756	$1,408	Reportable segments operating gain
1. 	Adjustment item resides in the Corporate & Other reportable segment.

-- 11 of 13 --

12	12
Elevance Health GAAP Reconciliation — Operating Gain, Operating
Expense Ratio, and 2024 Outlook
Nine Months Ended Sep 30	Three Months Ended Sep 30
Change	2023	2024	Change	2023	2024	(In millions)
0.9%	$15,088	$15,221	(3.7%)	$5,470	$5,269	Operating expense
Add / (Subtract):
(5)	(680)	(2)	(669)	Litigation and settlement expenses1
(697)	(268)	(697)	(268)	Business optimization charges 1
(154)	(158)	(73)	(42)	Transaction and integration related costs1
(856)	(1,106)	(772)	(979)	Net adjustment items
(0.8%)	$14,232	$14,115	(8.7%)	$4,698	$4,290	Adjusted operating expense
1.9%	$127,755	$130,215	5.3%	$42,480	$44,719	Operating revenue
(10) bp	11.8%	11.7%	(110) bp	12.9%	11.8%	Operating expense ratio
(30) bp	11.1%	10.8%	(150) bp	11.1%	9.6%	Adjusted operating expense ratio
Nine Months Ended Sep 30	Three Months Ended Sep 30
Change	2023	2024	Change	2023	2024	(In millions)
(0.4%)	$7,215	$7,189	(19.8%)	$1,756	$1,408	Reportable segments operating gain
Add / (Subtract):
5	680	2	669	Litigation and settlement expenses1
697	268	697	268	Business optimization charges 1
154	158	73	42	Transaction and integration related costs1
856	1,106	772	979	Net adjustment Items
2.8%	$8,071	$8,295	(5.6%)	$2,528	$2,387	Reportable segments adjusted operating gain
Full Year 2024
Outlook
Approximately $26.50	Shareholders’ earnings per diluted share
Add / (Subtract):
$2.93	Litigation and settlement expenses1
$2.21	Amortization of other intangibles
$1.93	Net losses on financial instruments
$1.15	Business optimization charges 1
$1.03	Transaction and integration related costs1
($0.86)	Gain on sale of business
Approximately ($1.89)	Tax impact of non-GAAP adjustments
$6.50	Net adjustment items
Approximately $33.00	Adjusted shareholders’ earnings per diluted share
1. 	Adjustment item resides in the Corporate & Other reportable segment.

-- 12 of 13 --



-- 13 of 13 --